Product
Supplier
Encyclopedia
Inquiry
Lenvatinib mesylate buy - large image1
Lenvatinib mesylate buy - image1
Lenvatinib mesylate buy - image2
Lenvatinib mesylate buy - image3
Lenvatinib mesylate buy - image4
Lenvatinib mesylate buy - image5
Lenvatinib mesylate buy - image6

Lenvatinib mesylate

Unit Price: Get Latest Price
CAS No.:

857890-39-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Beijing/Shanghai/Jinan/Qingdao/other importment

Brand:

Boyuan

Packaging:

25kg Carboard Crub

Price valid (until):

2024-03-31

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Terbinafine hydrochloride,Carboplatin,Pramipexole dihydrochloride Monohydrate,Cisatracurium Besylate,Rivaroxaban,Lenvatinib

  • Product Description

  • Seller Information

  • Description


      Product Detail  


    Product Name lenvatinibMesylate

    Product Synonyms

    lenvatinibMethanesulfonate; E7080Mesylate; 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamidemonomethanesulfonate; 4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamidemethanesulfonate; CAT#A863437; LenvatinibMesylate,AmadisChemicalofferCAS#857890-39-2; lenvatinibMesylate; E7080.

    CAS#857890-39-2

    Molecular Formula C22H23ClN4O7S

    Molecular weight 522.95862

    Melting point >220°C (dec.)

    Storage conditions -20°C Freezer

    Solubility DMSO (Slightly), Methanol (Slightly)

    Lenvatinib mesylate (lenvatinib) is an orally available, receptor‐type tyrosine kinase inhibitor, which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.

    E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.

    Lenvatinib Mesylate is used in preparation of anti-human CTLA4xPD-1 bispecific antibodies for diagnosis, prevention and treatment of tumor or anemia.

    ChEBI: Lenvatinib mesylate is a methanesulfonate salt obtained by reaction of lenvatinib with one molar equivalent of methanesulfonic acid. A multi-kinase inhibitor and orphan drug used (as its mesylate salt) for the treatment of various types of thyroid cancer that do not respond to radioiodine. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist, an orphan drug, a vascular endothelial growth factor receptor antagonist and an antineoplastic agent. It contains a lenvatinib(1+).


    Basic Info
    Product Name:

    Lenvatinib mesylate

    Other Name:

    6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,methanesulfonate (1:1);6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,monomethanesulfonate;Lenvatinib mesylate;E 7080 mesylate;Lenvatinib methanesulfonate;4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide mesylate;Kisplyx;Lenvima

    CAS No.:

    857890-39-2

    Molecular Formula:

    C21H19ClN4O4.CH4O3S

    InChIKeys:

    InChIKey=HWLFIUUAYLEFCT-UHFFFAOYSA-N

    Molecular Weight:

    522.95900

    Exact Mass:

    522.09800

    UNII:

    3J78384F61

    DSSTox ID:

    DTXSID90235081

    NCI Thesaurus Code:

    C48636

    ATC Code:

    L01XE|L01XE29

    Categories:

    Antineoplastic Agents

    Characteristics
    PSA:

    178.32000

    XLogP3:

    5.82090

    Hazard Identification

    Classification of the substance or mixture

    Reproductive toxicity, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H361 Suspected of damaging fertility or the unborn child

    Precautionary statement(s)
    Prevention

    P203 Obtain, read and follow all safety instructions before use.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P318 IF exposed or concerned, get medical advice.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Terbinafine hydrochloride,Carboplatin,Pramipexole dihydrochloride Monohydrate,Cisatracurium Besylate,Rivaroxaban,Lenvatinib

    Location:

    NO.28 SangYuan Rd,JinanCity,ShanDong Province,China

    Payment Terms:

    TT against copy of documents,D/P,L/C,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    1

    Total Annual Revenue:

    $50 million-$100 million

    Total Employees:

    501-1000

    Year of Establishment:

    2005

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.